CD137 ACTIVATION AUGMENTS THE EFFICACY OF EGFR-TARGETED THERAPY

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2014年 / 4卷 / 07期
关键词：
D O I：
10.1158/2159-8290.CD-RW2014-120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Major finding: Treatment with anti-CD137 mAb improves cetuximab efficacy by enhancing immune responses. Mechanism: Cetuximab induces CD137 on NK cells, and CD137 targeting stimulates ADCC and adaptive immunity. Impact: Dual antibody therapy may be beneficial in EGFR-positive cancers, including KRAS-mutant tumors. © 2014 American Association for Cancer Research.
引用
收藏
页码：758 / 758
页数：1
相关论文
共 50 条
  • [41] Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy
    Anderson, M. W.
    Freud, A. G.
    Zhao, S.
    Alizadeh, A. A.
    Kohrt, H. E.
    Warnke, R.
    Levy, R.
    Natkunam, Y.
    MODERN PATHOLOGY, 2011, 24 : 285A - 285A
  • [42] EGFR-TARGETED THERAPY-INDUCED RESISTANCE MECHANISM IN MALIGNANT GLIOMAS
    Hwang, Inah
    Wu, Lingxiang
    Cao, Dongqing
    Hu, Baoli
    Yao, Jun
    Yu, Yao
    Wang, Qianghu
    Zheng, Hongwu
    Paik, Jihye
    NEURO-ONCOLOGY, 2018, 20 : 75 - 75
  • [43] Pancreatic cancer EGFR pathway signaling in the absence of activating mutations: Implications for EGFR-targeted therapy
    Tzeng, Ching-Wei D.
    Frolov, Andrey
    Frolova, Natalya
    Jhala, Nirag C.
    Frost, Andra R.
    Howard, J. Harrison
    Schuller, Kyle W.
    Buchsbaum, Donald J.
    Vickers, Selwyn M.
    Heslin, Martin J.
    Arnoletti, J. Pablo
    CANCER RESEARCH, 2006, 66 (08)
  • [44] Activation of CD137/CD137L results in reduced tumor cell proliferation in human colon cancer
    Grimmig, Tanja
    Callies, Simone
    Naegele, Hannes
    Wagner, Martin
    Moench, Romana
    Polat, Buelent
    Germer, Christoph-Thomas
    Gasser, Martin
    Waaga-Gasser, Ana Maria
    CANCER RESEARCH, 2017, 77
  • [45] Establishment of CD137 humanized mouse model for efficacy assessment of agonistic anti-CD137 therapeutic antibodies
    Ouyang, Davy Xuesong
    Chen, Gang
    Wang, Zhensheng
    Zheng, Lei
    An, Annie Xiaoyu
    Wery, Jean-Pierre
    Liu, Jay
    Dong, Xin
    Li, Henry Q. X.
    CANCER RESEARCH, 2017, 77
  • [46] Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling
    Monast, C. S.
    Lazzara, M. J.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (10):
  • [47] Hypomagnesemia as a predictor of the efficacy of combination EGFR-targeted drugs versus EGFR ADCs alone in HNSCC.
    Jiang, Siqing
    Liu, Hanchun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 146 - 146
  • [48] Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation
    Langstein, J
    Becke, FM
    Söllner, L
    Krause, G
    Brockhoff, G
    Kreutz, M
    Andreesen, R
    Schwarz, H
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (01) : 117 - 122
  • [49] EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles
    Tsai, Wen-Hsuan
    Yu, Kun-Hua
    Huang, Yi-Cheng
    Lee, Cheng-I
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 903 - 916
  • [50] Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
    Chang, David Z.
    Kumar, Vikas
    Ma, Ying
    Li, Kuiyuan
    Kopetz, Scott
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
12345